Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1509591

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1509591

Biobetters Global Market Report 2024

PUBLISHED:
PAGES: 175 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

Biobetters are biologic drugs that are similar to existing biologics but have been enhanced to offer improved efficacy, safety, or other clinical benefits. These enhancements may include better dosing regimens, reduced side effects, increased stability, or more convenient administration methods, providing a competitive edge over the original biologics.

The main drug classes of biobetters include erythropoietin biobetters, granulocyte-colony stimulating factor (G-CSF) biobetters, interferon biobetters, insulin biobetters, monoclonal antibody biobetters, antihemophilic factors, and others. Erythropoietin biobetters are enhanced versions of erythropoietin, a hormone that increases red blood cell production. Various routes of administration for biobetters include oral, subcutaneous, inhaled, and intravenous. These drugs address a range of disease indications such as diabetes, cancer, renal disease, neurodegenerative diseases, genetic disorders, and hemophilia. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The biobetters market research report is one of a series of new reports from The Business Research Company that provides biobetters market statistics, including biobetters industry global market size, regional shares, competitors with a biobetters market share, detailed biobetters market segments, market trends and opportunities, and any further data you may need to thrive in the biobetters industry. This biobetters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biobetters market size has grown rapidly in recent years. It will grow from $60.73 billion in 2023 to $67.81 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to an increased understanding of disease mechanisms, growing healthcare expenditure, enhanced manufacturing technologies, technological innovations in drug delivery, advancements in protein engineering, and increased demand for improved therapeutic efficacy.

The biobetters market size is expected to see rapid growth in the next few years. It will grow to $105.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in biotechnology, a growing emphasis on personalized medicine, expanding pipelines of biopharmaceutical companies, the rising prevalence of chronic diseases, favorable regulatory landscapes, heightened investments in research and development, and advanced healthcare infrastructure. Major trends in the forecast period include the development of novel biobetters, progress in protein engineering and rational design, a focus on specific therapeutic areas, the development of next-generation sequencing (NGS) technologies, and advances in high-throughput screening (HTS) technologies.

The rising incidence of chronic kidney diseases is expected to propel the growth of the biobetters market going forward. Chronic kidney disease (CKD) is a long-term illness that impairs kidney function and eventually leads to kidney failure. The prevalence of CKD is increasing due to aging demographics, higher incidences of diabetes and hypertension, poor dietary habits, sedentary lifestyles, environmental pollution, and improved diagnostic capabilities. Biobetters aid in managing CKD by offering enhanced efficacy, reduced side effects, better dosing regimens, and improved stability compared to original biologic treatments, leading to better patient outcomes. For example, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency for public health, approximately 20,000 deaths in Australia in 2021 were linked to CKD, accounting for 12% of the total mortality rate that year. Therefore, the rising incidence of chronic kidney diseases is driving the growth of the biobetters market.

The increasing prevalence of autoimmune diseases is expected to propel the growth of the biobetters market going forward. Autoimmune diseases are disorders where the immune system mistakenly attacks healthy cells. The prevalence of autoimmune diseases is rising due to factors such as genetic predisposition, environmental influences, and lifestyle changes. Biobetters help manage autoimmune disorders by providing enhanced efficacy, reduced side effects, improved dosing regimens, and increased stability compared to original biologic treatments, leading to more effective and tolerable management of these conditions. For instance, in December 2023, according to the Australian Institute of Health and Welfare (AIHW), rheumatoid arthritis accounted for 2.0% of the total disease burden in 2023. In 2021, it caused 1,145 deaths, equivalent to 3.2 deaths per 100,000 people, representing 0.7% of all fatalities. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the biobetters market.

Major companies in the biobetters market are developing biobetters for subcutaneous administration to improve patient convenience, enhance therapeutic outcomes, and reduce healthcare costs. Subcutaneous administration of biobetters offers a more convenient alternative to intravenous infusion, potentially improving patient compliance and healthcare delivery efficiency. For instance, in May 2023, Celltrion, a South Korean-based biopharmaceutical company, obtained approval from the Brazilian Health Regulatory Agency for their Remsima SC biobetters. This innovative biobetter version of their infliximab biosimilar, Remsima, is the world's only infliximab offering subcutaneous administration. Remsima SC improves upon a biosimilar by enhancing its accessibility and effectiveness, specifically indicated for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. Remsima SC offers patients a more convenient and potentially more effective treatment option.

Major companies operating in the biobetters market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, F Hoffmann La Roche Ltd., Eli Lilly and Co Ltd., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc, CSL Behring GmbH, Biogen Inc., GRIFOLS USA LLC, Celltrion Inc., Lonza Group AG, Ionis Pharmaceuticals Inc., Incyte Corporation, Amicus Therapeutics Inc., Genentech Inc., Sun Pharmaceutical Industries

North America was the largest region in the biobetters market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biobetters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biobetters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biobetters market consists of sales of next-generation biologics, improved formulation products, and biosimilar drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biobetters Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biobetters market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biobetters? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biobetters market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Erythropoietin Biobetters; Granulocyte-Colony Stimulating Factor (G-CSF) Bioreactors; Interferon Biobetters; Insulin Biobetters; Monoclonal Antibodies Biobetters; Antihemophilic Factors; Other Drug Classes
  • 2) By Route of Administration: Oral; Subcutaneous; Inhaled; Intravenous; Other Routes
  • 3) By Disease Indication: Diabetes; Cancer; Renal Disease; Neurodegenerative Diseases; Genetic Disorder-Hemophilia; Other Diseases
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co Inc.; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.
Product Code: r18088

Table of Contents

1. Executive Summary

2. Biobetters Market Characteristics

3. Biobetters Market Trends And Strategies

4. Biobetters Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Biobetters Market Size and Growth

  • 5.1. Global Biobetters Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Biobetters Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Biobetters Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biobetters Market Segmentation

  • 6.1. Global Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Erythropoietin Biobetters
  • Granulocyte-Colony Stimulating Factor (G-CSF) Bioreactors
  • Interferon Biobetters
  • Insulin Biobetters
  • Monoclonal Antibodies Biobetters
  • Antihemophilic Factors
  • Other Drug Classes
  • 6.2. Global Biobetters Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Subcutaneous
  • Inhaled
  • Intravenous
  • Other Routes
  • 6.3. Global Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diabetes
  • Cancer
  • Renal Disease
  • Neurodegenerative Diseases
  • Genetic Disorder-Hemophilia
  • Other Diseases
  • 6.4. Global Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Biobetters Market Regional And Country Analysis

  • 7.1. Global Biobetters Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Biobetters Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biobetters Market

  • 8.1. Asia-Pacific Biobetters Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biobetters Market

  • 9.1. China Biobetters Market Overview
  • 9.2. China Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biobetters Market

  • 10.1. India Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biobetters Market

  • 11.1. Japan Biobetters Market Overview
  • 11.2. Japan Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biobetters Market

  • 12.1. Australia Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biobetters Market

  • 13.1. Indonesia Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biobetters Market

  • 14.1. South Korea Biobetters Market Overview
  • 14.2. South Korea Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biobetters Market

  • 15.1. Western Europe Biobetters Market Overview
  • 15.2. Western Europe Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biobetters Market

  • 16.1. UK Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biobetters Market

  • 17.1. Germany Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biobetters Market

  • 18.1. France Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biobetters Market

  • 19.1. Italy Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biobetters Market

  • 20.1. Spain Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biobetters Market

  • 21.1. Eastern Europe Biobetters Market Overview
  • 21.2. Eastern Europe Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biobetters Market

  • 22.1. Russia Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biobetters Market

  • 23.1. North America Biobetters Market Overview
  • 23.2. North America Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biobetters Market

  • 24.1. USA Biobetters Market Overview
  • 24.2. USA Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biobetters Market

  • 25.1. Canada Biobetters Market Overview
  • 25.2. Canada Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biobetters Market

  • 26.1. South America Biobetters Market Overview
  • 26.2. South America Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biobetters Market

  • 27.1. Brazil Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biobetters Market

  • 28.1. Middle East Biobetters Market Overview
  • 28.2. Middle East Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biobetters Market

  • 29.1. Africa Biobetters Market Overview
  • 29.2. Africa Biobetters Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Biobetters Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Biobetters Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biobetters Market Competitive Landscape And Company Profiles

  • 30.1. Biobetters Market Competitive Landscape
  • 30.2. Biobetters Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Biobetters Market Other Major And Innovative Companies

  • 31.1. Sanofi Aventis LLC
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. Novartis AG
  • 31.4. GlaxoSmithKline plc
  • 31.5. F Hoffmann La Roche Ltd.
  • 31.6. Eli Lilly and Co Ltd.
  • 31.7. Gilead Sciences Inc.
  • 31.8. Amgen Inc.
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Regeneron Pharmaceuticals Inc
  • 31.11. CSL Behring GmbH
  • 31.12. Biogen Inc.
  • 31.13. GRIFOLS USA LLC
  • 31.14. Celltrion Inc.
  • 31.15. Lonza Group AG

32. Global Biobetters Market Competitive Benchmarking

33. Global Biobetters Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biobetters Market

35. Biobetters Market Future Outlook and Potential Analysis

  • 35.1 Biobetters Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Biobetters Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Biobetters Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!